Income statement
USD
Annual
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 3M | 3M | 2M | 1M |
| Gross Profit | 3M | 3M | 3M | 2M | 1M |
| Operating Income | -3M | -4M | -5M | -7M | -6M |
| EBITDA | -3M | -4M | -5M | -7M | -6M |
| Net Income | -3M | -4M | -4M | -7M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Healthcare
Live Price
Offline$2.80
-6.98% today
1Y Change
+11.68%
Window
Jun 23, 2025 → Jun 16, 2026
Coverage: 247 bars · Jun 23, 2025 → Jun 16, 2026
Research Briefing
A compact read on the setup, peer context, quarterly changes, and recent earnings reaction.
Research Snapshot
Xenetic Biosciences, Inc. (XBIO) is a Healthcare stock with a market cap of $10.00M and listed on NASDAQ. The stock last traded around $2.80 and up 11.7% across the available one-year price window (Jun 23, 2025 → Jun 16, 2026). Baseline metrics include revenue growth of +19.0%, EPS growth of +38.5%, a dividend yield of 0.0%. What stands out right now is revenue +19.0%, EPS +38.5%, free cash flow +18.8% with operating margin -95.2% and ROIC -38.3%. Valuation is more restrained than many high-expectation growth names at price/sales 1.7. Overall, the current profile looks closer to a higher-growth but lower-margin setup than a generic broad-market placeholder. Stock Foundry combines XBIO price history, valuation, growth, dividend context, earnings, analyst forecasts, news, related Healthcare peers on this page.
Benchmark Comparison
Compare this ticker against a broad index, growth benchmark, or sector ETF using a shared 1Y normalization window.
XBIO
—
Normalized return
SPY
—
S&P 500
Excess Return
—
Relative to SPY
XBIO Max Drawdown
-80.50%
Trailing 1Y
SPY Max Drawdown
—
Trailing 1Y
Uses the longest available daily history for XBIO and SPY.
Financial profile
Profitability, balance sheet stamina, and cash efficiency drawn from the latest filings.
FY Revenue
$1.2M
-32.0% YoY
FY Net Income
-$5.6M
+13.8% YoY
Free Cash Flow
-$4.7M
+7.9% YoY
Revenue Growth
+19.0%
EPS Growth
+38.5%
Gross Margin
100.0%
Net Margin
-90.1%
Income statement
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Revenue | 3M | 3M | 3M | 2M | 1M |
| Gross Profit | 3M | 3M | 3M | 2M | 1M |
| Operating Income | -3M | -4M | -5M | -7M | -6M |
| EBITDA | -3M | -4M | -5M | -7M | -6M |
| Net Income | -3M | -4M | -4M | -7M | -6M |
| EPS (Diluted) | — | — | — | — | — |
Balance sheet
USD
| Metric | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|
| Cash & Equivalents | 8M | 6M | 9M | 13M | 18M |
| Total Assets | 8M | 7M | 11M | 15M | 20M |
| Total Liabilities | 968K | 894K | 810K | 1M | 1M |
| Shareholder Equity | 7M | 6M | 10M | 14M | 18M |
| Total Debt | 0 | 0 | 0 | 0 | 27K |
| Net Debt | -8M | -6M | -9M | -13M | -18M |
Cash flow positioning
Latest Full Year
Operating Cash Flow
5M
-2.0% YoY
Capital Expenditures
0
+100.0% YoY
Free Cash Flow
5M
+7.9% YoY
Key ratios
Gross Margin
100.0%
Operating Margin
-95.2%
Net Margin
-90.1%
ROE
-51.2%
Debt / Equity
0.00x
Next Step
Use the numbers to decide whether this is a growth candidate, a quality compounder, or just an interesting outlier.